Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 882
Rating:

Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA

Prof David Siegel talks to ecancer at the International Myeloma Workshop 2019 about reducing carfilzomib combined with lenalidomide and dexamethasone to once-weekly.

He outlines the obvious benefits of this regime and how he believes a transition on to this regimen will be adopted.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Oncology knowledge


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation